Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

unknown267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

NCT06349044
unknownphase_2

Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer

NCT04296240
unknownphase_2

The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

NCT02038621

Clinical Trials (3)

Showing 3 of 3 trials
NCT06349044Not Applicable

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting
NCT04296240Phase 2

Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer

Unknown
NCT02038621Phase 2

The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3